Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Review Article

Current Therapeutic Strategies and Possible Effective Drug Delivery Strategies against COVID-19

Author(s): Debabrata Ghosh Dastidar*, Dipanjan Ghosh, Swarnasree Ghosh and Gopal Chakrabarti*

Volume 20, Issue 10, 2023

Published on: 25 October, 2022

Page: [1441 - 1464] Pages: 24

DOI: 10.2174/1567201819666221004094509

Price: $65

Abstract

COVID-19 pandemic is the biggest global crisis. The frequent mutations in coronavirus to generate new mutants are of major concern. The pathophysiology of SARS-CoV-2 infection has been well studied to find suitable molecular targets and candidate drugs for effective treatment. FDArecommended etiotropic therapies are currently followed along with mass vaccination. The drug delivery system and the route of administration have a great role in enhancing the efficacy of therapeutic agents and vaccines. Since COVID-19 primarily infects the lungs in the affected individuals, pulmonary administration may be the best possible route for the treatment of COVID-19. Liposomes, solid lipid nanoparticles, polymeric nanoparticles, porous microsphere, dendrimers, and nanoparticles encapsulated microparticles are the most suitable drug delivery systems for targeted drug delivery. The solubility, permeability, chemical stability, and biodegradability of drug molecules are the key factors for the right selection of suitable nanocarriers. The application of nanotechnology has been instrumental in the successful development of mRNA, DNA and subunit vaccines, as well as the delivery of COVID-19 therapeutic agents.

Keywords: SARS-CoV-2, pulmonary administration, targeted drug delivery, plasma therapy, COVID-19, monoclonal antibody, vaccine.

Graphical Abstract
[1]
National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Human coronavirus types. 2020. Available from: https://www.cdc.gov/coronavirus/types.html
[2]
de Groot, R.J.; Baker, S.C.; Baric, R.S.; Brown, C.S.; Drosten, C.; Enjuanes, L.; Fouchier, R.A.M.; Galiano, M.; Gorbalenya, A.E.; Memish, Z.A.; Perlman, S.; Poon, L.L.M.; Snijder, E.J.; Stephens, G.M.; Woo, P.C.Y.; Zaki, A.M.; Zambon, M.; Ziebuhr, J. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J. Virol., 2013, 87(14), 7790-7792.
[http://dx.doi.org/10.1128/JVI.01244-13] [PMID: 23678167]
[3]
Pollett, S.; Conte, M.A.; Sanborn, M.; Jarman, R.G.; Lidl, G.M.; Modjarrad, K.; Maljkovic Berry, I. A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic. Sci. Rep., 2021, 11(1), 17365.
[http://dx.doi.org/10.1038/s41598-021-96626-8] [PMID: 34462471]
[4]
Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J. Virol., 2020, 94(7), e00127-20.
[http://dx.doi.org/10.1128/JVI.00127-20] [PMID: 31996437]
[5]
Jeffers, S.A.; Tusell, S.M.; Gillim-Ross, L.; Hemmila, E.M.; Achenbach, J.E.; Babcock, G.J.; Thomas, W.D., Jr; Thackray, L.B.; Young, M.D.; Mason, R.J.; Ambrosino, D.M.; Wentworth, D.E.; DeMartini, J.C.; Holmes, K.V. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA, 2004, 101(44), 15748-15753.
[http://dx.doi.org/10.1073/pnas.0403812101] [PMID: 15496474]
[6]
Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2), 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[7]
Blaess, M.; Kaiser, L.; Sauer, M.; Csuk, R.; Deigner, H.P. COVID-19/SARS-CoV-2 infection: Lysosomes and lysosomotropism implicate new treatment strategies and personal risks. Int. J. Mol. Sci., 2020, 21(14), 4953.
[http://dx.doi.org/10.3390/ijms21144953] [PMID: 32668803]
[8]
Yang, N.; Shen, H.M. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int. J. Biol. Sci., 2020, 16(10), 1724-1731.
[http://dx.doi.org/10.7150/ijbs.45498] [PMID: 32226290]
[9]
Ballout, R.A.; Sviridov, D.; Bukrinsky, M.I.; Remaley, A.T. The lysosome: A potential juncture between SARS‐CoV‐2 infectivity and Niemann‐Pick disease type C, with therapeutic implications. FASEB J., 2020, 34(6), 7253-7264.
[http://dx.doi.org/10.1096/fj.202000654R] [PMID: 32367579]
[10]
Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA, 2020, 117(21), 11727-11734.
[http://dx.doi.org/10.1073/pnas.2003138117] [PMID: 32376634]
[11]
Heald-Sargent, T.; Gallagher, T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses, 2012, 4(4), 557-580.
[http://dx.doi.org/10.3390/v4040557] [PMID: 22590686]
[12]
Belouzard, S.; Millet, J.K.; Licitra, B.N.; Whittaker, G.R. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses, 2012, 4(6), 1011-1033.
[http://dx.doi.org/10.3390/v4061011] [PMID: 22816037]
[13]
Kawase, M.; Shirato, K.; van der Hoek, L.; Taguchi, F.; Matsuyama, S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol., 2012, 86(12), 6537-6545.
[http://dx.doi.org/10.1128/JVI.00094-12] [PMID: 22496216]
[14]
Nakagawa, K.; Lokugamage, K.G.; Makino, S. Viral and cellular mRNA translation in coronavirus-infected cells. Adv. Virus Res., 2016, 96, 165-192.
[http://dx.doi.org/10.1016/bs.aivir.2016.08.001] [PMID: 27712623]
[15]
Wada, M.; Lokugamage, K.G.; Nakagawa, K.; Narayanan, K.; Makino, S. Interplay between coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway. Proc. Natl. Acad. Sci. USA, 2018, 115(43), E10157-E10166.
[http://dx.doi.org/10.1073/pnas.1811675115] [PMID: 30297408]
[16]
Kikkert, M. Innate immune evasion by human respiratory RNA viruses. J. Innate Immun., 2020, 12(1), 4-20.
[http://dx.doi.org/10.1159/000503030] [PMID: 31610541]
[17]
Li, F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol., 2016, 3(1), 237-261.
[http://dx.doi.org/10.1146/annurev-virology-110615-042301] [PMID: 27578435]
[18]
Huang, Y.; Yang, C.; Xu, X.; Xu, W.; Liu, S. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol. Sin., 2020, 41(9), 1141-1149.
[http://dx.doi.org/10.1038/s41401-020-0485-4] [PMID: 32747721]
[19]
Zhang, C.; Wang, Y.; Zhu, Y.; Liu, C.; Gu, C.; Xu, S.; Wang, Y.; Zhou, Y.; Wang, Y.; Han, W.; Hong, X.; Yang, Y.; Zhang, X.; Wang, T.; Xu, C.; Hong, Q.; Wang, S.; Zhao, Q.; Qiao, W.; Zang, J.; Kong, L.; Wang, F.; Wang, H.; Qu, D.; Lavillette, D.; Tang, H.; Deng, Q.; Xie, Y.; Cong, Y.; Huang, Z. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat. Commun., 2021, 12(1), 264.
[http://dx.doi.org/10.1038/s41467-020-20465-w] [PMID: 33431876]
[20]
Zhang, L.; Jackson, C.B.; Mou, H.; Ojha, A.; Rangarajan, E.S.; Izard, T.; Farzan, M.; Choe, H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv, 2020, 2020.2006.2012.148726.
[http://dx.doi.org/10.1101/2020.06.12.148726]
[21]
Zhang, L.; Jackson, C.B.; Mou, H.; Ojha, A.; Peng, H.; Quinlan, B.D.; Rangarajan, E.S.; Pan, A.; Vanderheiden, A.; Suthar, M.S.; Li, W.; Izard, T.; Rader, C.; Farzan, M.; Choe, H. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun., 2020, 11(1), 6013.
[http://dx.doi.org/10.1038/s41467-020-19808-4] [PMID: 33243994]
[22]
Mukherjee, S.; Liang, L.; Veiseh, O. Recent advancements of magnetic nanomaterials in cancer therapy. Pharmaceutics, 2020, 12(2), 147.
[http://dx.doi.org/10.3390/pharmaceutics12020147] [PMID: 32053995]
[23]
Cowman, K.; Guo, Y.; Liise-Anne, P.; Wong, D.; Bao, H.; Chen, V.; Hopkins, U.; Andrews, E.; Hamel, J.; Keller, M.; Bellin, E.; Thota, R.; Davis, P.; Rodriguez, E.T.; Suthar, P.; Allen, L.; Rossi, J.; Haviland, A.; Orner, E.; Szymczak, W.; Shujauddin, S.; McCarthy, J.; Binder, B.; Pushparaj, V.; Bard, L.; Pierino, V.F.; Alsina, L.; Esses, D.; McCaskie, A.; Campbell, C.; Madzura, T.; Wollowitz, A.; Basset, K.; White, De.; Ruiz, R.; Sosnowski, F.; Nori, P. Post-severe acute respiratory syndrome coronavirus 2 monoclonal antibody treatment hospitalizations as a sentinel for emergence of viral variants in New York City. Open Forum Infect. Dis., 2021, 8(8), ofab313.
[http://dx.doi.org/10.1093/ofid/ofab313]
[24]
Jangra, S.; Ye, C.; Rathnasinghe, R.; Stadlbauer, D.; Alshammary, H.; Amoako, A.A.; Awawda, M.H.; Beach, K.F.; Bermúdez-González, M.C.; Chernet, R.L.; Eaker, L.Q.; Ferreri, E.D.; Floda, D.L.; Gleason, C.R.; Kleiner, G.; Jurczyszak, D.; Matthews, J.C.; Mendez, W.A.; Mulder, L.C.F.; Russo, K.T.; Ashley-Beathrese, S.T.; Saksena, M.; Shin, A.S.; Sominsky, L.A.; Srivastava, K.; Krammer, F.; Simon, V.; Martinez-Sobrido, L.; García-Sastre, A.; Schotsaert, M. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe, 2021, 2(7), 283-284.
[http://dx.doi.org/10.1016/S2666-5247(21)00068-9]
[25]
Garcia-Beltran, W.F.; Lam, E.C.; St. Denis, K.; Nitido, A.D.; Garcia, Z.H.; Hauser, B.M.; Feldman, J.; Pavlovic, M.N.; Gregory, D.J.; Poznansky, M.C.; Sigal, A.; Schmidt, A.G.; John Iafrate, A.; Naranbhai, V.; Balazs, A.B. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, 2021, 184(9), 2523.
[26]
Davies, N.G.; Abbott, S.; Barnard, R.C.; Jarvis, C.I.; Kucharski, A.J.; Munday, J.D.; Pearson, C.A.B.; Russell, T.W.; Tully, D.C.; Washburne, A.D.; Wenseleers, T.; Gimma, A.; Waites, W.; Wong, K.L.M.; van Zandvoort, K.; Silverman, J.D.; Diaz-Ordaz, K.; Keogh, R.; Eggo, R.M.; Funk, S.; Jit, M.; Atkins, K.E.; John Edmunds, W. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. medRxiv, 2021. 2020.2012.2024.20248822.
[http://dx.doi.org/10.1101/2020.12.24.20248822]
[27]
Wang, P.; Nair, M.S.; Liu, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.; Kwong, P.D.; Graham, B.S.; Mascola, J.R.; Chang, J.Y.; Yin, M.T.; Sobieszczyk, M.; Kyratsous, C.A.; Shapiro, L.; Sheng, Z.; Huang, Y.; Ho, D.D. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. bioRxiv, 2021, 2021.2001.2025.428137.
[http://dx.doi.org/10.21203/rs.3.rs-155394/v1]
[28]
Wu, K.; Werner, A.P.; Moliva, J.I.; Koch, M.; Choi, A.; Stewart-Jones, G.B.E.; Bennett, H.; Boyoglu-Barnum, S.; Shi, W.; Graham, B.S.; Carfi, A.; Corbett, K.S.; Seder, R.A.; Edwards, D.K. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv, 2021. 2021.2001. 2025.427948
[http://dx.doi.org/10.1101/2021.01.25.427948]
[29]
Xie, X.; Zou, J.; Fontes-Garfias, C.R.; Xia, H.; Swanson, K.A.; Cutler, M.; Cooper, D.; Menachery, V.D.; Weaver, S.; Dormitzer, P.R.; Shi, P-Y. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv, 2021. 2021.2001.2007. 425740
[http://dx.doi.org/10.1101/2021.01.07.425740]
[30]
Madhi, S.A.; Baillie, V.; Cutland, C.L.; Voysey, M.; Koen, A.L.; Fairlie, L.; Padayachee, S.D.; Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; Briner, C.; Kwatra, G.; Ahmed, K.; Aley, P.; Bhikha, S.; Bhiman, J.N.; As’ad, E.B.; du Plessis, J.; Esmail, A.; Groenewald, M.; Horne, E.; Hwa, S-H.; Jose, A.; Lambe, T.; Laubscher, M.; Malahleha, M.; Masenya, M.; Masilela, M.; McKenzie, S.; Molapo, K.; Moultrie, A.; Oelofse, S.; Patel, F.; Pillay, S.; Rhead, S.; Rodel, H.; Rossouw, L.; Taoushanis, C.; Tegally, H.; Thombrayil, A.; van Eck, S.; Wibmer, C.K.; Durham, N.M.; Kelly, E.J.; Villafana, T.L.; Gilbert, S.; Pollard, A.J.; de Oliveira, T.; Moore, P.L.; Sigal, A.; Izu, A. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. medRxiv, 2021, 2021.2002.2010.21251247.
[http://dx.doi.org/10.1101/2021.02.10.21251247]
[31]
Greaney, A.J.; Loes, A.N.; Crawford, K.H.D.; Starr, T.N.; Malone, K.D.; Chu, H.Y.; Bloom, J.D. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. bioRxiv, 2021, 2020.2012.2031.425021.
[http://dx.doi.org/10.1101/2020.12.31.425021]
[32]
Wang, P.; Casner, R.G.; Nair, M.S.; Wang, M.; Yu, J.; Cerutti, G.; Liu, L.; Kwong, P.D.; Huang, Y.; Shapiro, L.; Ho, D.D. Increased resistance of SARS-CoV-2 variant. bioRxiv, 2021. 2021.2003.2001. 433466
[33]
Al-Tawfiq, J.A.; Al-Homoud, A.H.; Memish, Z.A. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med. Infect. Dis., 2020, 34, 101615.
[http://dx.doi.org/10.1016/j.tmaid.2020.101615] [PMID: 32145386]
[34]
Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal., 2020, 10(2), 102-108.
[http://dx.doi.org/10.1016/j.jpha.2020.03.001] [PMID: 32282863]
[35]
Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[36]
Huentelman, M.J.; Zubcevic, J.; Hernández Prada, J.A.; Xiao, X.; Dimitrov, D.S.; Raizada, M.K.; Ostrov, D.A. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension, 2004, 44(6), 903-906.
[http://dx.doi.org/10.1161/01.HYP.0000146120.29648.36] [PMID: 15492138]
[37]
Zheng, Y.; Shang, J.; Yang, Y.; Liu, C.; Wan, Y.; Geng, Q.; Wang, M.; Baric, R.; Li, F. Lysosomal proteases are a determinant of coronavirus tropism. J. Virol., 2018, 92(24), e01504-18.
[http://dx.doi.org/10.1128/JVI.01504-18] [PMID: 30258004]
[38]
Vaduganathan, M.; Vardeny, O.; Michel, T.; McMurray, J.J.V.; Pfeffer, M.A.; Solomon, S.D. Renin–angiotensin–aldosterone system inhibitors in patients with covid-19. N. Engl. J. Med., 2020, 382(17), 1653-1659.
[http://dx.doi.org/10.1056/NEJMsr2005760] [PMID: 32227760]
[39]
Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T.F.; Paredes, R.; Sweeney, D.A.; Short, W.R.; Touloumi, G.; Lye, D.C.; Ohmagari, N.; Oh, M.D.; Ruiz-Palacios, G.M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M.G.; Atmar, R.L.; Creech, C.B.; Lundgren, J.; Babiker, A.G.; Pett, S.; Neaton, J.D.; Burgess, T.H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H.C. Remdesivir for the treatment of covid-19 - Preliminary report. N. Engl. J. Med., 2020.
[40]
De Savi, C.; Hughes, D.L.; Kvaerno, L. Quest for a COVID-19 cure by repurposing small-molecule drugs: Mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org. Process Res. Dev., 2020, 24(6), 940-976.
[http://dx.doi.org/10.1021/acs.oprd.0c00233]
[41]
Spinner, C.D.; Gottlieb, R.L.; Criner, G.J.; Arribas López, J.R.; Cattelan, A.M.; Soriano Viladomiu, A.; Ogbuagu, O.; Malhotra, P.; Mullane, K.M.; Castagna, A.; Chai, L.Y.A.; Roestenberg, M.; Tsang, O.T.Y.; Bernasconi, E.; Le Turnier, P.; Chang, S.C.; SenGupta, D.; Hyland, R.H.; Osinusi, A.O.; Cao, H.; Blair, C.; Wang, H.; Gaggar, A.; Brainard, D.M.; McPhail, M.J.; Bhagani, S.; Ahn, M.Y.; Sanyal, A.J.; Huhn, G.; Marty, F.M. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA, 2020, 324(11), 1048-1057.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]
[42]
Abd-Elsalam, S.; Ahmed, O.A.; Mansour, N.O.; Abdelaziz, D.H.; Salama, M.; Fouad, M.H.A.; Soliman, S.; Naguib, A.M.; Hantera, M.S.; Ibrahim, I.S.; Torky, M.; Dabbous, H.M.; El Ghafar, M.S.A.; Abdul-Baki, E.A.; Elhendawy, M. Remdesivir efficacy in COVID-19 treatment: A randomized controlled trial. Am. J. Trop. Med. Hyg., 2021, 106(3), 886-890.
[http://dx.doi.org/10.4269/ajtmh.21-0606] [PMID: 34649223]
[43]
Sleeman, K.; Mishin, V.P.; Deyde, V.M.; Furuta, Y.; Klimov, A.I.; Gubareva, L.V. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother., 2010, 54(6), 2517-2524.
[http://dx.doi.org/10.1128/AAC.01739-09] [PMID: 20350949]
[44]
Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci., 2017, 93(7), 449-463.
[http://dx.doi.org/10.2183/pjab.93.027] [PMID: 28769016]
[45]
ClinicalTrials.gov. A study to evaluate the safety, pharmacokinetics and antiviral effects of galidesivir in yellow fever or COVID-19. 2020. Available from:https://clinicaltrials.gov/ct2/show/ NCT03891420 Retrieved 15th July 2020
[46]
BioCryst. BioCryst provides update on galidesivir program., 2020. Available from: https://ir.biocryst.com/news-releases/news-release-details/biocryst-provides-update-galidesivir-program Retrieved December 22, 2020.
[47]
de Wilde, A.H.; Jochmans, D.; Posthuma, C.C.; Zevenhoven-Dobbe, J.C.; van Nieuwkoop, S.; Bestebroer, T.M.; van den Hoogen, B.G.; Neyts, J.; Snijder, E.J. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother., 2014, 58(8), 4875-4884.
[http://dx.doi.org/10.1128/AAC.03011-14] [PMID: 24841269]
[48]
Kunz, K.M. A trial of lopinavir–ritonavir in covid-19. N. Engl. J. Med., 2020, 382(21), e68.
[http://dx.doi.org/10.1056/NEJMc2008043] [PMID: 32369282]
[49]
ClinicalTrials.gov. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19., 2020. Available from: https://www.who.int/news-room/detail/04-07-2020-whodiscontinues- hydroxychloroquine-and-lopinavir-ritonavirtreatment- arms-for-covid-19 Retrieved 31st August 2020
[50]
Chen, J.; Xia, L.; Liu, L.; Xu, Q.; Ling, Y.; Huang, D.; Huang, W.; Song, S.; Xu, S.; Shen, Y.; Lu, H. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. Open Forum Infect. Dis., 2020, 7(7), ofaa241.
[http://dx.doi.org/10.1093/ofid/ofaa241] [PMID: 32671131]
[51]
Savarino, A.; Boelaert, J.R.; Cassone, A.; Majori, G.; Cauda, R. Effects of chloroquine on viral infections: An old drug against today’s diseases. Lancet Infect. Dis., 2003, 3(11), 722-727.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[52]
Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2(1), 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[53]
ClinicalTrials.gov. Safety, tolerability and immunogenicinity of a coronavirus-like particle COVID-19 vaccine in adults aged 18-55 years. 2020. Available from: https://clinicaltrials.gov/ct2/show/ NCT04450004
[54]
ClinicalTrials.gov. Efficacy and safety of hydroxychloroquine and azithromycin for the treatment of ambulatory patients with mild COVID-19. 2020. Available from: https://clinicaltrials.gov/ct2/ show/NCT04348474 Retrieved 28th August, 2020
[55]
Hoffmann, M.; Kleine-Weber, H.; Krüger, N.; Müller, M.; Drosten, C.; Pöhlmann, S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, 2019. 2020.2001.2031.929042
[http://dx.doi.org/10.1101/2020.01.31.929042]
[56]
Gunst, J.D.; Staerke, N.B.; Pahus, M.H.; Kristensen, L.H.; Bodilsen, J.; Lohse, N.; Dalgaard, L.S.; Brønnum, D.; Fröbert, O.; Hønge, B.; Johansen, I.S.; Monrad, I.; Erikstrup, C.; Rosendal, R.; Vilstrup, E.; Mariager, T.; Bove, D.G.; Offersen, R.; Shakar, S.; Cajander, S.; Jørgensen, N.P.; Sritharan, S.S.; Breining, P.; Jespersen, S.; Mortensen, K.L.; Jensen, M.L.; Kolte, L.; Frattari, G.S.; Larsen, C.S.; Storgaard, M.; Nielsen, L.P.; Tolstrup, M.; Sædder, E.A.; Østergaard, L.J.; Ngo, H.T.T.; Jensen, M.H.; Højen, J.F.; Kjolby, M.; Søgaard, O.S. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine, 2021, 35, 100849.
[http://dx.doi.org/10.1016/j.eclinm.2021.100849] [PMID: 33903855]
[57]
Hoffmann, M.; Schroeder, S.; Kleine-Weber, H.; Müller, M.A.; Drosten, C.; Pöhlmann, S. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrob. Agents Chemother., 2020, 64(6), e00754-20.
[http://dx.doi.org/10.1128/AAC.00754-20] [PMID: 32312781]
[58]
Quinn, T.M.; Gaughan, E.E.; Bruce, A.; Antonelli, J.; O’Connor, R.; Li, F.; McNamara, S.; Koch, O.; MacIntosh, C.; Dockrell, D.; Walsh, T.; Blyth, K.G.; Church, C.; Schwarze, J.; Boz, C.; Valanciute, A.; Burgess, M.; Emanuel, P.; Mills, B.; Rinaldi, G.; Hardisty, G.; Mills, R.; Findlay, E.; Jabbal, S.; Duncan, A.; Plant, S.; Marshall, A.D.L.; Young, I.; Russell, K.; Scholefield, E.; Nimmo, A.F.; Nazarov, I.B.; Churchill, G.C.; McCullagh, J.S.O.; Ebrahimi, K.H.; Ferrett, C.; Templeton, K.; Rannard, S.; Owen, A.; Moore, A.; Finlayson, K.; Shankar-Hari, M.; Norrie, J.; Parker, R.A.; Akram, A.R.; Anthony, D.C.; Dear, J.W.; Hirani, N.; Dhaliwal, K. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, pharmacokinetics and pharmacodynamics. medRxiv, 2021, 2021.2010.2006.21264648.
[59]
Seifirad, S. Pirfenidone: A novel hypothetical treatment for COVID-19. Med. Hypotheses, 2020, 144, 110005-110005.
[http://dx.doi.org/10.1016/j.mehy.2020.110005] [PMID: 32575019]
[60]
ClinicalTrials.gov. A study to evaluate the efficacy and safety of pirfenidone with novel coronavirus infection. , 2020. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04282902
[61]
Zhang, F.; Wei, Y.; He, L.; Zhang, H.; Hu, Q.; Yue, H.; He, J.; Dai, H. A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019. Chin. Med. J. (Engl.), 2022, 135(3), 368-370.
[http://dx.doi.org/10.1097/CM9.0000000000001614] [PMID: 34855641]
[62]
Ely, E.W.; Ramanan, A.V.; Kartman, C.E.; de Bono, S.; Liao, R.; Piruzeli, M.L.B.; Goldman, J.D.; Saraiva, J.F.K.; Chakladar, S.; Marconi, V.C.; Alatorre-Alexander, J.; Altclas, J.D.; Casas, M. CevoliRecio, V.; Ellerin, T.; Giovanni Luz, K.; Goldman, J.D.; Juliani Souza Lima, M.P.; Khan, A.; Paulin, P.; Procopio Carvalho, A.C.; Rojas Velasco, G.; Saraiva, J.F.K.; Shawa, I.; Simon Campos, J.; Tiffany, B.; Westheimer Cavalcante, A. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial. Lancet Respir. Med., 2022, 10(4), 327-336.
[http://dx.doi.org/10.1016/S2213-2600(22)00006-6] [PMID: 35123660]
[63]
Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W.; Bao, L.; Zhang, B.; Liu, G.; Wang, Z.; Chappell, M.; Liu, Y.; Zheng, D.; Leibbrandt, A.; Wada, T.; Slutsky, A.S.; Liu, D.; Qin, C.; Jiang, C.; Penninger, J.M. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat. Med., 2005, 11(8), 875-879.
[http://dx.doi.org/10.1038/nm1267] [PMID: 16007097]
[64]
ClinicalTrials.gov. Effects of discontinuing renin-angiotensin system inhibitors in patients with COVID-19., 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04351581 Retrieved 31st August, 2020
[65]
Vankadari, N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int. J. Antimicrob. Agents, 2020, 56(2), 105998.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105998] [PMID: 32360231]
[66]
Nojomi, M.; Yassin, Z.; Keyvani, H.; Makiani, M.J.; Roham, M.; Laali, A.; Dehghan, N.; Navaei, M.; Ranjbar, M. Effect of Arbidol (Umifenovir) on COVID-19: A randomized controlled trial. BMC Infect. Dis., 2020, 20(1), 954.
[http://dx.doi.org/10.1186/s12879-020-05698-w] [PMID: 33317461]
[67]
Yang, C.; Ke, C.; Yue, D.; Li, W.; Hu, Z.; Liu, W.; Hu, S.; Wang, S.; Liu, J. Effectiveness of arbidol for COVID-19 prevention in health professionals. Front. Public Health, 2020, 8, 249.
[http://dx.doi.org/10.3389/fpubh.2020.00249] [PMID: 32574310]
[68]
Alavi Darazam, I.; Shokouhi, S.; Mardani, M.; Pourhoseingholi, M.A.; Rabiei, M.M.; Hatami, F.; Shabani, M.; Moradi, O.; Gharehbagh, F.J.; Irvani, S.S.N.; Amirdosara, M.; Hajiesmaeili, M.; Rezaei, O.; Khoshkar, A.; Lotfollahi, L.; Gachkar, L.; Dehbsneh, H.S.; Khalili, N.; Soleymaninia, A.; Kusha, A.H.; Shoushtari, M.T.; Torabinavid, P. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int. Immunopharmacol., 2021, 99, 107969.
[http://dx.doi.org/10.1016/j.intimp.2021.107969] [PMID: 34273635]
[69]
Ali, K.; Azher, T.; Baqi, M.; Binnie, A.; Borgia, S.; Carrier, F.M.; Cavayas, Y.A.; Chagnon, N.; Cheng, M.P.; Conly, J.; Costiniuk, C.; Daley, P.; Daneman, N.; Douglas, J.; Downey, C.; Duan, E.; Duceppe, E.; Durand, M.; English, S.; Farjou, G.; Fera, E.; Fontela, P.; Fowler, R.; Fralick, M.; Geagea, A.; Grant, J.; Harrison, L.B.; Havey, T.; Hoang, H.; Kelly, L.E.; Keynan, Y.; Khwaja, K.; Klein, G.; Klein, M.; Kolan, C.; Kronfli, N.; Lamontagne, F.; Lau, R.; Fralick, M.; Lee, T.C.; Lee, N.; Lim, R.; Longo, S.; Lostun, A.; MacIntyre, E.; Malhamé, I.; Mangof, K.; McGuinty, M.; Mergler, S.; Munan, M.P.; Murthy, S.; O’Neil, C.; Ovakim, D.; Papenburg, J.; Parhar, K.; Parvathy, S.N.; Patel, C.; Perez-Patrigeon, S.; Pinto, R.; Rajakumaran, S.; Rishu, A.; Roba-Oshin, M.; Rushton, M.; Saleem, M.; Salvadori, M.; Scherr, K.; Schwartz, K.; Semret, M.; Silverman, M.; Singh, A.; Sligl, W.; Smith, S.; Somayaji, R.; Tan, D.H.S.; Tobin, S.; Todd, M.; Tran, T.V.; Tremblay, A.; Tsang, J.; Turgeon, A.; Vakil, E.; Weatherald, J.; Yansouni, C.; Zarychanski, R. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial. CMAJ, 2022, 194(7), E242-E251.
[http://dx.doi.org/10.1503/cmaj.211698] [PMID: 35045989]
[70]
Gottlieb, R.L.; Vaca, C.E.; Paredes, R.; Mera, J.; Webb, B.J.; Perez, G.; Oguchi, G.; Ryan, P.; Nielsen, B.U.; Brown, M.; Hidalgo, A.; Sachdeva, Y.; Mittal, S.; Osiyemi, O.; Skarbinski, J.; Juneja, K.; Hyland, R.H.; Osinusi, A.; Chen, S.; Camus, G.; Abdelghany, M.; Davies, S.; Behenna-Renton, N.; Duff, F.; Marty, F.M.; Katz, M.J.; Ginde, A.A.; Brown, S.M.; Schiffer, J.T.; Hill, J.A. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med., 2022, 386(4), 305-315.
[http://dx.doi.org/10.1056/NEJMoa2116846] [PMID: 34937145]
[71]
Hassanipour, S.; Arab-Zozani, M.; Amani, B.; Heidarzad, F.; Fathalipour, M.; Martinez-de-Hoyo, R. The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials. Sci. Rep., 2021, 11(1), 11022.
[http://dx.doi.org/10.1038/s41598-021-90551-6] [PMID: 34040117]
[72]
Parienti, J.J.; Prazuck, T.; Peyro-Saint-Paul, L.; Fournier, A.; Valentin, C.; Brucato, S.; Verdon, R.; Sève, A.; Colin, M.; Lesne, F.; Guinard, J.; Ar Gouilh, M.; Dina, J.; Vabret, A.; Hocqueloux, L. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine, 2021, 38, 100993.
[http://dx.doi.org/10.1016/j.eclinm.2021.100993] [PMID: 34222849]
[73]
Tardif, J.C.; Bouabdallaoui, N.; L’Allier, P.L.; Gaudet, D.; Shah, B.; Pillinger, M.H.; Lopez-Sendon, J.; da Luz, P.; Verret, L.; Audet, S.; Dupuis, J.; Denault, A.; Pelletier, M.; Tessier, P.A.; Samson, S.; Fortin, D.; Tardif, J.D.; Busseuil, D.; Goulet, E.; Lacoste, C.; Dubois, A.; Joshi, A.Y.; Waters, D.D.; Hsue, P.; Lepor, N.E.; Lesage, F.; Sainturet, N.; Roy-Clavel, E.; Bassevitch, Z.; Orfanos, A.; Stamatescu, G.; Grégoire, J.C.; Busque, L.; Lavallée, C.; Hétu, P.O.; Paquette, J.S.; Deftereos, S.G.; Levesque, S.; Cossette, M.; Nozza, A.; Chabot-Blanchet, M.; Dubé, M.P.; Guertin, M.C.; Boivin, G. Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir. Med., 2021, 9(8), 924-932.
[http://dx.doi.org/10.1016/S2213-2600(21)00222-8] [PMID: 34051877]
[74]
Dorward, J.; Yu, L.M.; Hayward, G.; Saville, B.R.; Gbinigie, O.; Van Hecke, O.; Ogburn, E.; Evans, P.H.; Thomas, N.P.B.; Patel, M.G.; Richards, D.; Berry, N.; Detry, M.A.; Saunders, C.; Fitzgerald, M.; Harris, V.; Shanyinde, M.; de Lusignan, S.; Andersson, M.I.; Butler, C.C.; Hobbs, F.D.R. Colchicine for COVID-19 in the community (PRINCIPLE): A randomised, controlled, adaptive platform trial. Br. J. Gen. Pract., 2022, 72(720), e446-e455.
[http://dx.doi.org/10.3399/BJGP.2022.0083] [PMID: 35440469]
[75]
Group, RECOVERY Collaborative. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet Respir. Med., 2021, 9(12), 1419-1426.
[76]
Dequin, P.F.; Heming, N.; Meziani, F.; Plantefève, G.; Voiriot, G.; Badié, J.; François, B.; Aubron, C.; Ricard, J.D.; Ehrmann, S.; Jouan, Y.; Guillon, A.; Leclerc, M.; Coffre, C.; Bourgoin, H.; Lengellé, C.; Caille-Fénérol, C.; Tavernier, E.; Zohar, S.; Giraudeau, B.; Annane, D.; Le Gouge, A. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19. JAMA, 2020, 324(13), 1298-1306.
[http://dx.doi.org/10.1001/jama.2020.16761] [PMID: 32876689]
[77]
Crothers, K.; DeFaccio, R.; Tate, J.; Alba, P.R.; Goetz, M.B.; Jones, B.; King, J.T., Jr; Marconi, V.; Ohl, M.E.; Rentsch, C.T.; Rodriguez-Barradas, M.C.; Shahrir, S.; Justice, A.C.; Akgün, K.M. Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support. Eur. Respir. J., 2021.
[PMID: 34824060]
[78]
Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J.K.; Haynes, R.; Landray, M.J. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med., 2021, 384(8), 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[79]
Maskin, L.P.; Bonelli, I.; Olarte, G.L.; Palizas, F., Jr; Velo, A.E.; Lurbet, M.F.; Lovazzano, P.; Kotsias, S.; Attie, S.; Lopez Saubidet, I.; Baredes, N.D.; Setten, M.; Rodriguez, P.O. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: A multicenter, randomized open-label clinical trial. J. Intensive Care Med., 2022, 37(4), 491-499.
[http://dx.doi.org/10.1177/08850666211066799] [PMID: 34898320]
[80]
Hammond, Jennifer; Leister-Tebbe, Heidi; Gardner, Annie; Abreu, Paula; Bao, Weihang Wisemandle, Wayne Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. 2022, 386(15), 1397-1408..
[81]
Jayk Bernal, A.; Gomes da Silva, M.M.; Musungaie, D.B.; Kovalchuk, E.; Gonzalez, A.; Delos Reyes, V.; Martín-Quirós, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M.L.; Du, J.; Pedley, A.; Assaid, C.; Strizki, J.; Grobler, J.A.; Shamsuddin, H.H.; Tipping, R.; Wan, H.; Paschke, A.; Butterton, J.R.; Johnson, M.G.; De Anda, C. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med., 2022, 386(6), 509-520.
[http://dx.doi.org/10.1056/NEJMoa2116044] [PMID: 34914868]
[82]
Group, RECOVERY Collaborative. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 2021, 397(10274), 605-612.
[83]
Group, PRINCIPLE Trial Collaborative. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. Lancet, 2021, 397(10279), 1063-1074.
[84]
Cavalcanti, A.B.; Zampieri, F.G.; Rosa, R.G.; Azevedo, L.C.P.; Veiga, V.C.; Avezum, A.; Damiani, L.P.; Marcadenti, A.; Kawano-Dourado, L.; Lisboa, T.; Junqueira, D.L.M. de Barros e Silva, P.G.M.; Tramujas, L.; Abreu-Silva, E.O.; Laranjeira, L.N.; Soares, A.T.; Echenique, L.S.; Pereira, A.J.; Freitas, F.G.R.; Gebara, O.C.E.; Dantas, V.C.S.; Furtado, R.H.M.; Milan, E.P.; Golin, N.A.; Cardoso, F.F.; Maia, I.S.; Hoffmann Filho, C.R.; Kormann, A.P.M.; Amazonas, R.B.; Bocchi de Oliveira, M.F.; Serpa-Neto, A.; Falavigna, M.; Lopes, R.D.; Machado, F.R.; Berwanger, O.; Berwanger, O. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N. Engl. J. Med., 2020, 383(21), 2041-2052.
[http://dx.doi.org/10.1056/NEJMoa2019014] [PMID: 32706953]
[85]
Yang, S.N.Y.; Atkinson, S.C.; Wang, C.; Lee, A.; Bogoyevitch, M.A.; Borg, N.A.; Jans, D.A. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res., 2020, 177, 104760.
[http://dx.doi.org/10.1016/j.antiviral.2020.104760] [PMID: 32135219]
[86]
Vallejos, J.; Zoni, R.; Bangher, M.; Villamandos, S.; Bobadilla, A.; Plano, F.; Campias, C.; Chaparro Campias, E.; Medina, M.F.; Achinelli, F.; Guglielmone, H.A.; Ojeda, J.; Farizano Salazar, D.; Andino, G.; Kawerin, P.; Dellamea, S.; Aquino, A.C.; Flores, V.; Martemucci, C.N.; Martinez, S.M.; Segovia, J.E.; Reynoso, P.I.; Sosa, N.C.; Robledo, M.E.; Guarrochena, J.M.; Vernengo, M.M.; Ruiz Diaz, N.; Meza, E.; Aguirre, M.G. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect. Dis., 2021, 21(1), 635.
[http://dx.doi.org/10.1186/s12879-021-06348-5] [PMID: 34215210]
[87]
Westendorf, Kathryn; Žentelis, Stefanie; Wang, Lingshu; Foster, Denisa; Vaillancourt, Peter; Wiggin, Matthew; Lovett, Erica; van der Lee, Robin; Hendle, Jörg; Pustilnik, Anna; Sauder, J. Michael; Kraft, Lucas; Hwang, Yuri; Siegel, Robert W.; Chen, Jinbiao; Heinz, Beverly A.; Higgs, Richard E.; Kallewaard, Nicole L.; Jepson, Kevin; Goya, Rodrigo; Smith, Maia A.; Collins, David W.; Pellacani, Davide; Xiang, Ping; de Puyraimond, Valentine; Ricicova, Marketa; Devorkin, Lindsay; Pritchard, Caitlin; O’Neill, Aoise; Dalal, Kush; Panwar, Pankaj; Dhupar, Harveer; Garces, Fabian A.; Cohen, Courtney A.; Dye, John M.; Huie, Kathleen E.; Badger, Catherine V.; Kobasa, Darwyn; Audet, Jonathan; Freitas, Joshua J.; Hassanali, Saleema; Hughes, Ina; Munoz, Luis; Palma, Holly C.; Ramamurthy, Bharathi; Cross, Robert W.; Geisbert, Thomas W.; Menacherry, Vineet; Lokugamage, Kumari; Borisevich, Viktoriya; Lanz, Iliana; Anderson, Lisa; Sipahimalani, Payal; Corbett, Kizzmekia S.; Yang, Eun Sung; Zhang, Yi; Shi, Wei; Zhou, Tongqing; Choe, Misook; Misasi, John; Kwong, Peter D.; Sullivan, Nancy J.; Graham, Barney S.; Fernandez, Tara L.; Hansen, Carl L.; Falconer, Ester; Mascola, John R.; Jones, Bryan E.; Barnhart, Bryan C. LYCoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep., 2022, 39(7), 110812.
[http://dx.doi.org/10.1016/j.celrep.2022.110812]
[88]
Wang, X.; Guo, X.; Xin, Q.; Pan, Y.; Hu, Y.; Li, J.; Chu, Y.; Feng, Y.; Wang, Q. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin. Infect. Dis., 2020, 71(10), 2688-2694.
[http://dx.doi.org/10.1093/cid/ciaa721] [PMID: 32497196]
[89]
Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; Wei, J.; Xiao, H.; Yang, Y.; Qu, J.; Qing, L.; Chen, L.; Xu, Z.; Peng, L.; Li, Y.; Zheng, H.; Chen, F.; Huang, K.; Jiang, Y.; Liu, D.; Zhang, Z.; Liu, Y.; Liu, L. Treatment of 5 critically ill patients with covid-19 with convalescent plasma. JAMA, 2020, 323(16), 1582-1589.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID: 32219428]
[90]
Lead, India to. World’s largest’ convalescent plasma covid-19 clinical trial. 2020. Available from: https://www.biospectrumasia.com/news/49/16116/india-to-lead-worlds-largest-convalescent-plasma-covid-19-clinical-trial.html
[91]
Dougan, M.; Nirula, A.; Azizad, M.; Mocherla, B.; Gottlieb, R.L.; Chen, P.; Hebert, C.; Perry, R.; Boscia, J.; Heller, B.; Morris, J.; Crystal, C.; Igbinadolor, A.; Huhn, G.; Cardona, J.; Shawa, I.; Kumar, P.; Adams, A.C.; Van Naarden, J.; Custer, K.L.; Durante, M.; Oakley, G.; Schade, A.E.; Holzer, T.R.; Ebert, P.J.; Higgs, R.E.; Kallewaard, N.L.; Sabo, J.; Patel, D.R.; Dabora, M.C.; Klekotka, P.; Shen, L.; Skovronsky, D.M. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N. Engl. J. Med., 2021, 385(15), 1382-1392.
[http://dx.doi.org/10.1056/NEJMoa2102685]
[92]
Dougan, M.; Azizad, M.; Chen, P.; Feldman, B.; Frieman, M.; Igbinadolor, A.; Kumar, P.; Morris, J.; Potts, J.; Baracco, L.; Macpherson, L.; Kallewaard, N.L.; Patel, D.R.; Hufford, M.M.; Wietecha, L.; Chigutsa, E.; Demmon, S.L.; Jones, B.E.; Nirula, A.; Skovronsky, D.M.; Williams, M.; Gottlieb, R.L. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv, 2022.
[http://dx.doi.org/10.1101/2022.03.10.22272100]
[93]
McEneny-King, A.C.; Monteleone, J.P.R.; Kazani, S.D.; Ortiz, S.R. Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe coronavirus disease 2019. Infect. Dis. Ther., 2021, 10(2), 1045-1054.
[http://dx.doi.org/10.1007/s40121-021-00425-7] [PMID: 33826106]
[94]
Elneil, S.; Lalezari, J.P.; Pourhassan, N.Z. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab. J. Transl. Autoimmun., 2021, 4, 100097.
[http://dx.doi.org/10.1016/j.jtauto.2021.100097] [PMID: 33778462]
[95]
Gritti, G.; Raimondi, F.; Ripamonti, D.; Riva, I.; Landi, F.; Alborghetti, L.; Frigeni, M.; Damiani, M.; Micò, C.; Fagiuoli, S.; Cosentini, R.; Lorini, F.L.; Fabretti, F.; Morgan, J.; Owens, B.M.J.; Kanhai, K.; Cowburn, J.; Rizzi, M.; Di Marco, F. Rambaldi, Alessandro Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv, 2020.
[96]
Temesgen, Z.; Assi, M.; Vergidis, P.; Rizza, S.A.; Bauer, P.R.; Pickering, B.W.; Razonable, R.R.; Libertin, C.R.; Burger, C.D.; Orenstein, R.; Vargas, H.E.; Varatharaj Palraj, B.R.; Dababneh, A.S.; Chappell, G.; Chappell, D.; Ahmed, O.; Sakemura, R.; Durrant, C.; Kenderian, S.S.; Badley, A. First clinical use of lenzilumab to neutralize GM-CSF in patients with severe COVID-19 pneumonia. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.06.08.20125369]
[97]
Generali, D.; Bosio, G.; Malberti, F.; Cuzzoli, A.; Testa, S.; Romanini, L.; Fioravanti, A.; Morandini, A.; Pianta, L.; Giannotti, G.; Viola, E.M.; Giorgi-Pierfranceschi, M.; Foramitti, M.; Tira, R.A.; Zangrandi, I.; Chiodelli, G.; Machiavelli, A.; Cappelletti, M.R.; Giossi, A.; De Giuli, V.; Costanzi, C.; Campana, C.; Bernocchi, O.; Sirico, M.; Zoncada, A.; Molteni, A.; Venturini, S.; Giudici, F.; Scaltriti, M.; Pan, A. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. Int. J. Infect. Dis., 2021, 104, 433-440.
[http://dx.doi.org/10.1016/j.ijid.2020.12.073] [PMID: 33385581]
[98]
Pang, J.; Xu, F.; Aondio, G.; Li, Y.; Fumagalli, A.; Lu, M.; Valmadre, G.; Wei, J.; Bian, Y.; Canesi, M.; Damiani, G.; Zhang, Y.; Yu, D.; Chen, J.; Ji, X.; Sui, W.; Wang, B.; Wu, S.; Kovacs, A.; Revera, M.; Wang, H.; Jing, X.; Zhang, Y.; Chen, Y.; Cao, Y. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat. Commun., 2021, 12(1), 814.
[http://dx.doi.org/10.1038/s41467-021-21085-8] [PMID: 33547300]
[99]
Perrone, F.; Piccirillo, M.C.; Ascierto, P.A.; Salvarani, C.; Parrella, R.; Marata, A.M.; Popoli, P.; Ferraris, L.; Marrocco-Trischitta, M.M.; Ripamonti, D.; Binda, F.; Bonfanti, P.; Squillace, N.; Castelli, F.; Muiesan, M.L.; Lichtner, M.; Calzetti, C.; Salerno, N.D.; Atripaldi, L.; Cascella, M.; Costantini, M.; Dolci, G.; Facciolongo, N.C.; Fraganza, F.; Massari, M.; Montesarchio, V.; Mussini, C.; Negri, E.A.; Botti, G.; Cardone, C.; Gargiulo, P.; Gravina, A.; Schettino, C.; Arenare, L.; Chiodini, P.; Gallo, C.; Perrone, F.; Piccirillo, M.C.; Schettino, C.; Gravina, A.; Gargiulo, P.; Cardone, C.; Arenare, L.; Ascierto, P.A.; Vitale, M.G.; Trojaniello, C.; Palla, M.; Bianchi, A.A.M.; Botti, G.; De Feo, G.; Miscio, L.; Gallo, C.; Chiodini, P.; Ferraris, L.; Marrocco-Trischitta, M.M.; Froldi, M.; Menicanti, L.; Cuppone, M.T.; Gobbo, G.; Baldessari, C.; Valenti, V.; Castelvecchio, S.; Poli, F.; Giacomazzi, F.; Piccinni, R.; Annnunziata, M.L.; Biondi, A.; Bussolari, C.; Mazzoleni, M.; Giachi, A.; Filtz, A.; Manini, A.; Poletti, E.; Masserini, F.; Conforti, F.; Gaudiano, G.; Favero, V.; Moroni, A.; Viva, T.; Fancoli, F.; Ferrari, D.; Niro, D.; Resta, M.; Ballotta, A.; Poli, M.D.; Ranucci, M.; Ripamonti, D.; Binda, F.; Tebaldi, A.; Gritti, G.; Pasulo, L.; Gaglio, L.; Del Fabbro, R.; Alborghetti, L.; Bonfanti, P.; Squillace, N.; Giustinetti, G.; Columpsi, P.; Cazzaniga, M.; Capici, S.; Sala, L.; Di Sciacca, R.; Mosca, G.; Pirozzi, M.R.; Castelli, F.; Muiesan, M.L.; Franceschini, F.; Roccaro, A.; Salvetti, M.; Paini, A.; Corda, L.; Ricci, C.; Tomasoni, L.; Nasta, P.; Lorenzotti, S.; Odolini, S.; Focà, E.; Roldan, E.Q.; Metra, M.; Magrini, S.; Borghetti, P.; Latronico, N.; Piva, S.; Filippini, M.; Zuccalà, F.; Cattaneo, S.; Scolari, F.; Bossini, N.; Gaggiotti, M.; Properzi, M.; Lichtner, M.; Del Borgo, C.; Marocco, R.; Belvisi, V.; Tieghi, T.; De Masi, M.; Zuccalà, P.; Fabietti, P.; Vetica, A.; Mercurio, V.S.; Carraro, A.; Fondaco, L.; Kertusha, B.; Curtolo, A.; Del Giudice, E.; Lubrano, R.; Zotti, M.G.; Puorto, A.; Ciuffreda, M.; Sarni, A.; Monteforte, G.; Romeo, D.; Viola, E.; Damiani, C.; Barone, A.; Mantovani, B.; Di Sanzo, D.; Gentili, V.; Carletti, M.; Aiuti, M.; Gallo, A.; Meliante, P.G.; Martellucci, S.; Riggio, O.; Cardinale, V.; Ridola, L.; Bragazzi, M.C.; Gioia, S.; Valenzi, E.; Graziosi, C.; Bina, N.; Fasolo, M.; Ricci, S.; Gioacchini, M.T.; Lucci, A.; Corso, L.; Tornese, D.; Nijhawan, P.; Equitani, F.; Cosentino, C.; Palladino, M.; Leonetti, F.; Leto, G.; Gnessi, C.; Campagna, G.; Cesareo, R.; Marrocco, F.; Straface, G.; Mecozzi, A.; Cerbo, L.; Isgrò, V.; Parrocchia, S.; Visconti, G.; Casati, G.; Calzetti, C.; Ariani, A.; Donghi, L.; Salerno, N.D.; Tacconelli, E.; Bertoldi, M.; Cattaneo, P.; Lambertenghi, L.; Motta, L.; Omega, L.; Albano, G.; Parrella, R.; Fraganza, F.; Atripaldi, L.; Montesarchio, V.; Scarano, F.; De Rosa, A.; Buglione, A.; Lavoretano, S.; Gaglione, G.; De Marco, M.; Sangiovanni, V.; Fusco, F.M.; Viglietti, R.; Manzillo, E.; Rescigno, C.; Pisapia, R.; Plamieri, G.; Maraolo, A.; Calabria, G.; Catalano, M.; Fiorentino, G.; Annunziata, A.; Polistina, G.; Imitazione, P.; Mollica, M.; Esposito, V.; D’Abraccio, M.; Punzi, R.; Bianco, V.; Sbreglia, C.; Del Vecchio, R.F.; Bordonali, A.; Franco, A.; Salvarani, C.; Massari, M.; Dolci, G.; Salsi, P.; Virzì, G.; Ornella, C.; Molteni, A.; Gennarini, S.; Gnudi, U.; Ricci, M.A.; Titolo, G.; Mensi, G.; Vuotto, P.; Gasperini, B.; Mancini, M.; Pasquini, Z.; Spanu, P.; Clementi, S.; Pierini, S.; Bokor, D.; Gori, D.; Ciofetti, M.; Caimi, M.; Bettazzi, L.; Allevi, E.; Furiani, S.; Capitanio, C.; Mastropasqua, B.; Fara, C.; Pulitanò, G.; Matsuno, J.S.; Porta, F.D.; Dolfini, V.; Beyene, N.B.; Bezzi, M.; Novali, M.; Viale, P.; Tedeschi, S.; Pascale, R.; Bruno, R.; Di Filippo, A.; Sachs, M.; Oggionni, T.; Di Stefano, M.; Mengoli, C.; Facchini, C.; Daniele, D.N.; Frausini, G.; Mucci, L.; Tedesco, S.; Girolimetti, R.; Manfredini, E.; Di Carlo, A.M.; Espinosa, E.; Dennetta, D.; Ticinesi, A.; Meschi, T.; Nouvenne, A.; Claudio, N.; Vitale, F.; Saracco, M.; Codeluppi, M.; Fronti, E.; Ferrante, P.; Nespola, G.A.; Francisci, D.; Tosti, A.; Carbonelli, C.M.; Greco, A.; Tinti, M.G.; Stellini, R.; Appiani, C.; Reghenzi, P.; Poletti, V.; Ravaglia, C.; Tacconi, D.; Malcontenti, C.; Sainaghi, P.P.; Landi, R.; Vassia, V.; Rizzi, E.; Bellan, M.; Rossati, A.; Castello, L.; Mastroianni, C.M.; Russo, G.; Fabio, T.; Serino, F.S.; Brollo, L.; Momesso, E.; Turati, M.L.; Monforte, A.D.; Marchetti, G.; Boni, F.; Teopompi, E.; Trenti, C.; Boracchia, L.; Minelli, E.; Fontana, M.; Ghidoni, G.; Matei, A.; Caruso, A.; Arcoleo, G.; Camarda, G.; Catalano, F.; Spatafora, M.; Bettega, D.; Andreoni, M.; Teti, E.; Sarmati, L.; Di Lorenzo, A.; Celeste, M.; Baratto, F.; Monticelli, J.; Criveller, P.; Andrea, A. Anselmo; Riccio; Castellano, M.; Cappelli, C.; Corvini, F.; Zanini, B.; Crippa, M.; Ronconi, M.; Costa, R.; Casella, S.; Brentana, L.; Bernardi, L.; Frascati, A.; Panese, S.; Presotto, F.; Michieletto, L.; Bernardi, C.; Fusar, M.; Agnoletti, V.; Farina, M.; Russo; Lavorini, F.; Ginanni, R.; Palmieri, F.; Mosti, S.; Amaglio, A.; Cattaneo, A.; Cirri, S.; Montisci, A.; Gallazzi, C.; Cosseta, D.; Baronio, B.; Rampa, L.; Maggi, P.; Messina, V.; Negri, E.A.; Sabatti, M.C.; Palumbo, M.; Mazzone, A.; Faggioli, P.; Bussini, L.; Fornaro, G.; Volpato, F.; Imperiale, D.; Manno, E.; Ferreri, E.; Martelli, D.; Verhovez, A.; Giorgis, S.; Faccio, L.; Quadri, R.D.; Negro, C.; Converso, M.; Bosco, F.; Prandini, P.; Cocchi, S.; Manfrin, V.; Del Punta, V.; Mazzola, G.; Sportato, G.; Romagnoli, M.; Cristini, F.; Facondini, F.; Perin, T.; Boschi, A.; Mussini, C.; Meschiari, M.; Guaraldi, G.; Modica, S.; Moneta, S.; Boccalatte, D.; Ricci, C.; Marchetti, V.; Amadasi, S.; Ebbreo, G.; Dalè, M.; Tura, P.; Rizzoni, D.; Boari, G.E.M.; Bonetti, S.; Marini, E.; Daniele, I.; Grossi, P.A.; Delfrate, N.W.; Bernhart, O.; Spizzo, G.; Mahlknecht, K.; Volkl, T.; Di Pietro, M.A.; Trezzi, M.; Monacci, C.; Peris, A.; Bonizzoli, M.; Cavanna, L.; Moroni, C.; Stroppa, E.M.; Manini, A.; Savio, M.C.; Gatti, F.; Bartolaminelli, C.; Petrosillo, N.; Donno, D.R.; Taglietti, F.; Topino, S.; Chinello, P.; Galati, V.; D’offizi, G.; Taibi, C.; Cimolato, B.; Moroni, F.; Palagano, N.; Pelagatti, L.; Cristiana, S.; Landini, G.; Amitrano, M.; Raimondo, M.; Mangiacapra, S.; Romano, A.; Atteno, M.; Casinelli, K.; Uccella, I.; Harari, S.; Caminati, A.; Lipani, F.; Di Perri, G.; Calcagno, A.; Calleri, G.; Montrucchio, C.; Caputo, A.M.; Cozzio, S.; Donne, L.D.; Bassetti, M.; Malgorzata, M.; Nicolini, L.A.; Russo, C.; Sepulcri, C.; Beltramini, S.; Mina, F.; Puoti, M.; Gandino, A.; Langer, T.; D’amico, F.; Berlendis, M.; Rocchetti, C.; Cettolo, F.; Gabriele, F.; Bocchi, P.; Cioni, G.; Cappi, C.; Corcione, S.; De Rosa, F.G.; Scabini, S.; Canta, F.; Pinna, S.M.; Pensa, A.; Blanc, P.; Suardi, L.R.; Pallotto, C.; Rocco, M.; Cirasa, M.T.; Spinicci, M.; Mencarini, J.; Zammarchi, L.; Giovanni, C.; Sciolè, K.; Bassi, F.; Bianchi, M.; Frigerio, S.; Spaziani, S.; Nucera, A.; Rizzardini, G.; Cossu, M.V.; Antivalle, M.; Carpinteri, G.; Macheda, S.; Labate, D.; Bottiroli, M.; Romano, A.; Erne, E.M.; Cristina, Z.; Di Biase, V.; Malberti, F.; Montani, G.; Poisa, P.; Bettini, D.; Cauda, R.; Ciccullo, A.; Riccardi, N.; Angheben, A.; Turrini, M.; Clerici, R.; Gardellini, A.; Liparulo, L.; Rossini, T.; Ucciferri, C.; Cipollone, F.; Vecchiet, J.; Nico, A.; Marra, L.; Leone, A.; Sdanganelli, A.; Palmiotti, G.A.; D’Alagni, G.; Santantonio, T.A.; Lo Caputo, S.; Bottalico, I.; Ponticiello, A.; Di Perna, F.; Bernardi, E.; Beltrame, A.; Bravi, S.; David, M.; Bernardi, P.; Galante, D.; Uccelli, M.C.; Prestini, K.; Drera, M.; Zini, E.; Peregrinelli, A.; Blanzuoli, L.; Benedetti, V.; Calvi, R.; Scaglione, N.; Nallino, G.; Bonazzi, M.; Crespi, T.; Masolin, T.; Regazzetti, A.; Cerri, M.C.; Maffezzini, E.; Piazza, M.; Papetti, C.; De Filippi, C.; Roveda, E.; Cipolla, G.; Scozzafava, M.; Crepaldi, M.; Henchi, S.; Vanoni, N.; Repossi, A.; Vezzoli, M.; Scorletti, E.; Perugini, O.; Pasini, S.M.; Pacetti, V.; Ferrari, L.; de Paduanis, G.A.; del Duca, S.; dell’Ara, F.; Brocchieri, A.; Minoja, G.; Storti, E.; Pitagora, L.; Costa, I.; Delfanti, F.; Orlandi, M.; Ruggeri, R.; Ruggieri, L.; Livigni, S.; Silengo, D.; Ageno, W.; Pedrini, L.; Artiol, S.; Morbidoni, L.; De Donno, G.; Ravagnani, V.; Inglese, F.; Scotton, P.G.; Costantini, P.; Delucchi, M.; Clini, E.; Ansuini, A.; Marco, B.; Giuseppe, L.; Vincenzo, B.; Rastelli, G.; Doria, A.; Vianello, A.; Cattelan, A.M.; Bindoli, S.; Felicietti, M.; Canetta, C.; Scartabellati, A.; Accordino, S.; Ferrara, M.; Cocco, L.; Cirillo, F.; Pace, E.; De Caro, M.; Alberico, M.; Benigni, G.; Damiano, T.; Fusco, P.; Iuorio, A.; Torretta, G.; Racagni, M.; Muttini, S.; Sala, G.; Ghiringhelli, P.; Chiumiento, F.; Baccari, L.; Luca, B.; Bocchi, F.; Benatti, F.; Catellani, J.; Coppola, M.; Papi, A.; Bosco, E.; Bonizzoli, M.; Lazzeri, C.; Cesira, N.; Puttini, C.; Carli, T.; Croci, L.; Corridi, M.; Arlotti, M.; Guerrini, G.; Cola, L.; Romanelli, M.; Bonifazi, M.; Gasparini, S.; Mei, F.; Cerutti, E.; Lacedonia, D.; Santoro, A.; Guidelli, G.M.; Greco, S.; Castellan, A.; Infantino, G.; Camici, L.; Frigieri, F.C.; Pavoni, V.; Migliori, L.; Rossetti, B.; Montagnini, F.; Mauro, I.; Genovese, E.; Capuozzo, A.; Vitiello, L.; Sirignano, E.; Gnesin, P.; Servillo, G.; Marinelli, A.; Pasero, D.; Babudieri, S.; Madeddu, G.; De Vito, A.; Casadio, L.; Ranghitta, M.; Passalacqua, R.; Antonio, F.; Gentile, I.; Buonomo, A.R.; Scotto, R.; Zappulo, E.; Dell’Aquila, G.; Bianchetti, A.; Guerini, F.; Vallone, A.; Oppedisano, P.; Pusterla, L.; Giglio, O.; Russo, G.; Sartori, E.; Zanardini, C.; Gatti, P.; Vincenzo, V.; Piconi, S.; Molteni, C.; Dognini, G.; Cosimo, F.; Guarneri, L.; Pulvirenti, F.; Mondino, V.; Traballi, G.; Iemoli, E.; Grisolia, A.; Giorgi, R.; Nucera, G.; Raffaelli, V.; Marino, P.; Negro, E.; Serati, L.; Silvia, T.; Iacobello, C.; Strano, G.; Boglione, L.; Catania, A.; Gipponi, P.; Di Cato, L.; Panaccione, A.; Vitale, G.; Crippa, I.A.; Giacomini, M.; Basile, A.; Andrea, B.; Tundo, P.; Buzzigoli, S.; Palmiero, G.; Magnaca, A.; Silva, M.; Ricci, M.; Crespi, S.; Pasquino, B.; Consales, G.; Bragantini, D.; Mastroianni, F.; Righetti, G.; Scarafino, A.; Bitetto, M.; Franzetti, F.; Piga, S.; Delmonte, V.; Carbonara, S.; Losappio, R.; Dejaco, C.; Mastroianni, C.; Del Bono, V.; Gilioli, F.; Barzan, D.; De Struppi, S.; Carlotto, A.; Guadagnin, M.L.; Girardis, M.; Bertellini, E.; Dentali, F.; Foresta, G.; Baratta, A.; Viviani, R.; Agrati, A.M.; Perego, G.B.; Montineri, A.; Manuele, R.; Bonfante, S.; Aquilini, D.; Prozzo, A.; Santopuoli, D.; Di Rosa, Z.; Alborghetti, A.; Peci, P.; Bakhtadze, N.; Pandini, C.S.; Casati, G.; Ashofarir, N.; Casella, G.; Spagnolli, W.; Urru, S.; Marchesoni, I.; Caminiti, G.; Argilloni, E.; Danieli, E.; Ghirardi, G.; Antonioli, C.M.; Lipari, A.; Zavarise, P.; Kokaly, F.; Polati, E.; Gottin, L.; Lucernoni, P.; De Conti, F.; Marcon, E.; Pontali, E.; Vacca, E.B.; Saffioti, C.; Zunino, A.; Pognuz, E.R.; Berlot, G.; Saltori, M.; Tedesco, A.; Agostini, C.; Di Rosolini, M.A.; Marino, F.; Bellinzona, G.; Grassi, W.; Di Carlo, M.; Scimonello, G.; Nonini, S.; Mondino, M.; Mantovani, L.F.; Tenti, E.; Tropea, C.M.G.; Di Stefano, D.E.; Guelfi, P.; Dagna, L.; Morgana, G.; Montemurro, L.; Girelli, D.; Crisafulli, E.; Maroccia, A.; Cemuschi, A.M.; Bernasconi, M.; Zummo, U.; Barbato, V.; Bevilacqua, S.; Buonfanti, G.; Canzanella, G.; De Matteis, G.; Florio, M.; Martino, M.; Ribecco, M.T.; Romano, F.; Savio, A.; Sparavigna, L.; Curvietto, M.; Citarella, M.; Nava, V.; Maggioni, P.; Magni, M.; Iommelli, C.; Bianco, A.; Corsini, R.; Valli, L.; Ruggieri, M.P.; Melica, T.; Ferrari, A.; Cicognini, D.; Delliponti, M.; Zuccarini, A.; Ciani, S.; Raffaeli, D.; Donati, L.; Cannizzo, S.; Lui, S.; Santini, L.; Roncaglia, E.; Mighali, P.; Eisendle, F.; Cerino, G.; Citterio, C.; Di Nunzio, C.; Mancini, A.; Lamonica, S.; Resimini, S.; Sarteschi, G.; Pavei, C.; Battistini, N.; Gazzola, O.E.; Miceli, M.; Pontiggia, S.; Lonati, V.; Giannandrea, G.; Sortino, C.; Ravani, S.; Uggeri, C.; Jocollé, G.; Baré, C.; Baroni, I.; De Candia, D.; Fiorini, B.; Chierico, K.; Romeo, F.; Bottega, R.; Boccasile, L.; Corsaro, A.; Spadoni, C.; Chiari, S.; Ercolino, G.; Dell’uomo, V.; Viri, S.; Minato, M.; Gazzola, L.; Dorina, B.; Gianelli, D.; Maspero, S.; Farinazzo, M.; Zanini, P.; Sangiovanni, A.; Del Giudice, A.; Dragonetti, M.M.; Bordignon, S.; Machiavelli, A.M.; Chiodelli, G.; Spatarella, M.; Zenoni, D.; Beretta, F.N.; Santilli, G.; Badagliacca, R.; Angileri, M.; Giannelli, L.; Campomori, A.; Maimone, P.; Fadda, A.; Faoro, S.; Pisterna, A.; Cacopardo, B.; Marino, A.; Pampaloni, A.; Celesia, B.M.; Cinnella, G.; Labella, D.; Caporusso, R.R.; Danzi, M.; Fiscon, M.; Malena, M.; Fendt, D.; Nardi, S.; Stobbione, P.; Savi, M.L.; De Monte, A.; Scala, A.; Liberato, N.L.; Luchi, S.; Vincenti, A.; Cabrini, L.; Pinelli, G.; Brugioni, L.; Potenza, D.; Numis, F.G.; Porta, G.; D’amico, M.; Iengo, B.; Angarano, G.; Saracino, A.; Blasi, L.; De Negri, P.; Angelici, S.; Farina, A.; Martino, G.P.; Bitti, G.; Tedeschi, A.; De Ponti, S.; Agostinone, A.; Parruti, G.; Consorte, A.; Frattari, A.; Filippelli, A.; Pagliano, P.; Masullo, A.; Sellitto, C.; Reta, M.; Rossi, N.; Raumer, L.; Andreassi, S.; Brancaleoni, P.; Carai, A.; Salerno, A.M.; Marinangeli, F.; Mariani, R.; Ciccone, A.; Meschini, C.; Santoboni, G.; Angrisani, C.; Micarelli, D.; Tarquini, G.; Fregoni, V.; Volta, C.A.; Cherubini, A.; Del Prete, M.S.; Ciarrochi, E.; Tasca, F.; Ballarin, A.; Bianchin, A.; Flocco, R.; Cuzzone, V.; Carpinteri, M.; Gallotti, P.; Torre, F.; Zannetti, P.; Crapis, M.; Venturini, S.; Barattini, M.; Gori, G.; Mastroianni, A.; De Stefano, G.; Gilio, M.; Rapisarda, G.; Gulisano, L.; Granata, M.L.; Saglimbene, S.; Montalto, M.T.; Grasso, I.; De Luca, S.; Magro, G.; Messina, F.; Scapino, B.; Abrate, P.; Francisco, C.; Pesce, L.; Navarra, M.; Agosti, M.; Pagani, S.; Piluso, M.; Ricioppo, A.; Tognella, S.; Rovere, P.; Vincenzi, M.; Ghirardi, L.; Generali, D.; Ingrosso, M.; Desiderio, E.; Molaro, R.; Vitiello, S.; Mastroianni, A.; Lancione, L.; Paone, T.C.; Meli, A.; Mainardi, S.; Rastellino, V.; Ursillo, A.; di Grigoli, P.; Bovetto, E.; Stefanetto, I.M.; Mazzola, F.; Daniele, A.; Bisio, C.; Delnero, P.; Morando, G.; Nava, A.; Francesco, L.; Fiammengo, F.; Regis, M.; Roccatello, D.; Sabato, E.; Liccardi, M.M.; Bretto, C.; Lutri, L.; Castenetto, E.; Roberti, G.; Guidi, M.F.; Bini, F.; Zappa, M.C.; Trequattrini, T.; Rivitti, R.; Vigliarolo, R.; Succu, A.; Lilli, M.; Serao, M.; Giogré, G.; Ruggieri, A.; Flores, K.; Vairo, G.; Satira, R.; Lingua, A.; Spina, R.; Nicastri, E.; Maffongelli, G.; Barreca, F.; Scollet, S.; Franchi, F.; Fabbri, C.; Minuz, P.; Dalbeni, A.; Zanatta, P.; Gelormini, D.; Mandelli, A.; Galderisi, F.; Zoia, E.; Marchi, M.R.; De Almeida Neves, N.; Carbone, G.; Di Caterino, E.; Petrone, A.; Usai, C.A.; Bandiera, F.; Monti, R.; Hofer, A.; Castiglione, G.; Angeletti, C.; Tarsia, P.; Veronese, L.; Artoni, P.D.; Larussa, D.; Fumagalli, R.; Brioschi, P.; Cerutti, A.; Pasquino, P.; Gilberto, F.; Cantadori, L.; Tomasoni, G.; Tomasoni, L.R.; Coppola, N.; Spolveri, S.; Pollastri, C.; Fico, L.; Principi, T.; Pierantozzi, S.; Fontana, C.; Lubrano, G.; Martinelli, L.; Bravi, S.; Navalesi, P.; Serra, E.; Cogi, E.; Manzi, A.; Furino, E.; Dasseni, N.; Gentilini, C.; Benatti, E.; Pignatti, A.; Aiello, G.; Milia, M.; Covesnon, M.G.; Brianti, A.; Francesco, C.; Ilaria, B.; Pagnozzi, F.; Mietta, S.; Rossi, A.; Maroni, L.; Borroni, V.; Bellintani, C.; Sgarabotto, C.; Bizzotto, G.; Bucci, L.; Spagnuolo, G.; Agostini, M.; Caria, F.C.; Testa, F.; De Palma, R.; Murdaca, G.; Zanolini, G.; Sala, N.; Righini, E.; Pontremoli, R.; Aondio, G.; Riccardi, F.; De Cristoforo, M.G.; De Michele, F.; Storti, A.; Perra, R.; Deidda, S.; Enrica, C.; Valastro, F.; Pierfranceschi, M.G.; De Gennaro, F.; Nardecchia, A.L.; Castellini, M.; Buetto, G.; Ippoliti, G.; Sicheri, D.; Bottoli, M.G.; De Arroyabe, B.M.L.; Versaci, A.; Di Cura Villa Giada Pallotti, C.; Civita, M.; Grio, M.; Liuzzi, N.; Molino, P.; Pastorelli, M.; Ricchiardi, A.; Varbella, F.; Zeme, A.D.; Sighieri, C.; Portale, G.; Olivetti, A.; Pagnoni, C.; Moschini, G.; Boni, S.; Guerra, A.; Scudellari, R.; Vella, S.; Inchiostro, S.; Piazza, O.; Guarino, S.; Aldegheri, G.; Napoli, G.; Morettini, A.; Caldini, E.; Menicacci, L.; Pieralli, F.; Torrini, M.; Poggesi, L.; Visetti, E.M.; Mangano, C.; Visconti, S.; Maietta, P.; Banfi, E.; Cartella, S.; Venturi, B.; Nuceri, A.; Chiesa, E.; Pacentra, E.; Panzolato, G.; Giannotti, M.; Bianchi, C.; Pietrangelo, A.; Para, O.; Rutili, M.S.; Russo, R.; Lanfranco, M.; Scalabrino, E.; Tafuri, A.; Perfetti, E.; Chiarello, T.; Cancanelli, L.; Otero, M.; Pannella, G.; Bellucci, F.; Ferrero, G.; Vico, C.; Stillante, M.S.; D’Andrea, G.; Amoroso, F.; Arcidiacono, A.; Bella, A.M.; Belsito, A.; Berté, Y.; Carubia, G.; Caruso, M.G.; Casella, O.; Chiereleson, F.; Costa, C.; De Franco, D.; Germanà, G.; Messina, A.; Musumeci, D.; Noto, C.; Valenti, M.; Sorrentino, C.; Panico, R.; Schettino, G.; Piccoli, J.; Pepe, A.; De Rosa, F.; Ottaviano, M.; Marrazzo, G.; Raponi, G.; Diberardino, S.; Bausi, S.; Ferrari, A.; Marini, S.F.; Giubellino, E.; Innocenti, G.; Gugliemi, G.; Maccari, D.; Baciu, I. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J. Transl. Med., 2020, 18(1), 405.
[http://dx.doi.org/10.1186/s12967-020-02573-9] [PMID: 33087150]
[100]
Norton, T.; Ali, S.; Sivapalasingam, S.; Gao, H.; Bhore, R.; Hooper, A.T.; Hamilton, J.D.; Musser, B.J.; Rofail, D. Im, Joseph; Perry, Christina; Pan, Cynthia; Hosain, Romana; Mahmood, Adnan; Davis, John D.; Turner, Kenneth C.; Baum, Alina; Kyratsous, Christos A.; Kim, Yunji; Cook, Amanda; Kampman, Wendy; Graber, Ximena; Acloque, Gerard; Sachdeva, Yessica; Bocchini, Joseph A.; Kohli, Anita; Kowal, Bari REGEN-COV antibody combination in outpatients with covid-19 – phase 1/2 results. medRxiv, 2022.
[http://dx.doi.org/10.1101/2021.06.09.21257915]
[101]
Boyapati, A.; Wipperman, M.F.; Ehmann, P.J.; Hamon, S.; Lederer, D.J.; Waldron, A.; Flanagan, J.J.; Karayusuf, E.; Bhore, R.; Nivens, M.C.; Hamilton, J.D.; Sumner, G.; Sivapalasingam, S. Baseline severe acute respiratory syndrome viral load is associated with coronavirus disease 2019 severity and clinical outcomes: Post hoc analyses of a phase 2/3 trial. J. Infect. Dis., 2021, 224(11), 1830-1838.
[http://dx.doi.org/10.1093/infdis/jiab445] [PMID: 34496013]
[102]
Bian, H.; Zheng, Z.H.; Wei, D.; Wen, A.; Zhang, Z.; Lian, J.Q.; Kang, W.Z.; Hao, C.Q.; Wang, J.; Xie, R.H.; Dong, K.; Xia, J.L.; Miao, J.L.; Kang, W.; Li, G.; Zhang, D.; Zhang, M.; Sun, X.X.; Ding, L.; Zhang, K.; Jia, J.; Ding, J.; Li, Z.; Jia, Y.; Liu, L.N.; Zhang, Z.; Gao, Z.W.; Du, H.; Yao, N.; Wang, Q.; Wang, K.; Geng, J.J.; Wang, B.; Guo, T.; Chen, R.; Zhu, Y.M.; Wang, L.J.; He, Q.; Yao, R.R.; Shi, Y.; Yang, X.M.; Zhou, J.S.; Ma, Y.N.; Wang, Y.T.; Liang, X.; Huo, F.; Wang, Z.; Zhang, Y.; Yang, X.; Zhang, Y.; Gao, L.H.; Wang, L.; Chen, X.C.; Tang, H.; Liu, S.S.; Wang, Q.Y.; Chen, Z.N.; Zhu, P. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: A randomized phase 1 and an exploratory phase 2 trial. Signal Transduct. Target. Ther., 2021, 6(1), 194.
[http://dx.doi.org/10.1038/s41392-021-00603-6] [PMID: 34001849]
[103]
Patton, J.S.; Fishburn, C.S.; Weers, J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc., 2004, 1(4), 338-344.
[http://dx.doi.org/10.1513/pats.200409-049TA] [PMID: 16113455]
[104]
Labiris, N.R.; Dolovich, M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 2003, 56(6), 588-599.
[http://dx.doi.org/10.1046/j.1365-2125.2003.01892.x] [PMID: 14616418]
[105]
Sahakijpijarn, S.; Moon, C.; Koleng, J.J.; Christensen, D.J.; Williams, R.O., III Development of remdesivir as a dry powder for inhalation by thin film freezing. Pharmaceutics, 2020, 12(11), 1002.
[http://dx.doi.org/10.3390/pharmaceutics12111002] [PMID: 33105618]
[106]
Ali, Z.A.; El-Mallakh, R.S. Nebulized lidocaine in covid-19, an hypothesis. Med. Hypotheses, 2020, 144, 109947.
[http://dx.doi.org/10.1016/j.mehy.2020.109947]
[107]
Ramakrishnan, S.; Nicolau, D.V., Jr; Langford, B.; Mahdi, M.; Jeffers, H.; Mwasuku, C.; Krassowska, K.; Fox, R.; Binnian, I.; Glover, V.; Bright, S.; Butler, C.; Cane, J.L.; Halner, A.; Matthews, P.C.; Donnelly, L.E.; Simpson, J.L.; Baker, J.R.; Fadai, N.T.; Peterson, S.; Bengtsson, T.; Barnes, P.J.; Russell, R.E.K.; Bafadhel, M. Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial. Lancet Respir. Med., 2021, 9, 763-712.
[http://dx.doi.org/10.1016/S2213-2600(21)00160-0]
[108]
He, S.; Gui, J.; Xiong, K.; Chen, M.; Gao, H.; Fu, Y. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J. Nanobiotechnology, 2022, 20(1), 101.
[http://dx.doi.org/10.1186/s12951-022-01307-x] [PMID: 35241085]
[109]
Yu, J.; Lu, X.; Tong, L.; Shi, X.; Ma, J.; Lv, F.; Wu, J.; Pan, Q.; Yang, J.; Auid-Orcid Cao, H.; Li, L. Interferon-α-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019. Br. J. Clin. Pharmacol., 2021, 87(12), 4737-4746.
[http://dx.doi.org/10.1111/bcp.14898]
[110]
Stone, K.C.; Mercer, R.R.; Gehr, P.; Stockstill, B.; Crapo, J.D. Allometric relationships of cell numbers and size in the mammalian lung. Am. J. Respir. Cell Mol. Biol., 1992, 6(2), 235-243.
[http://dx.doi.org/10.1165/ajrcmb/6.2.235] [PMID: 1540387]
[111]
Groneberg, D.A.; Witt, C.; Wagner, U.; Chung, K.F.; Fischer, A. Fundamentals of pulmonary drug delivery. Respir. Med., 2003, 97(4), 382-387.
[http://dx.doi.org/10.1053/rmed.2002.1457] [PMID: 12693798]
[112]
Chono, S.; Tanino, T.; Seki, T.; Morimoto, K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target., 2006, 14(8), 557-566.
[http://dx.doi.org/10.1080/10611860600834375] [PMID: 17043040]
[113]
Lauweryns, J.M.; Baert, J.H. Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis., 1977, 115(4), 625-683.
[PMID: 322558]
[114]
Rejman, J.; Oberle, V.; Zuhorn, I.S.; Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J., 2004, 377(1), 159-169.
[http://dx.doi.org/10.1042/bj20031253] [PMID: 14505488]
[115]
Lee, E.S.; Kwon, M.J.; Na, K.; Bae, J.H. Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex. Colloids Surf. B Biointerfaces, 2007, 55(1), 125-130.
[http://dx.doi.org/10.1016/j.colsurfb.2006.11.024] [PMID: 17178450]
[116]
Dastidar, D.G.; Das, A.; Datta, S.; Ghosh, S.; Pal, M.; Thakur, N.S.; Banerjee, U.C.; Chakrabarti, G. Paclitaxel-encapsulated core–shell nanoparticle of cetyl alcohol for active targeted delivery through oral route. Nanomedicine (Lond.), 2019, 14(16), 2121-2150.
[http://dx.doi.org/10.2217/nnm-2018-0419] [PMID: 31411540]
[117]
Shah, M.; Agrawal, Y.K.; Garala, K.; Ramkishan, A. Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride. Indian J. Pharm. Sci., 2012, 74(5), 434-442.
[http://dx.doi.org/10.4103/0250-474X.108419] [PMID: 23716872]
[118]
Magalhães, J.; Pinheiro, M.; Drasler, B.; Septiadi, D.; Petri-Fink, A.; Santos, S.G.; Rothen-Rutishauser, B.; Reis, S. Lipid nanoparticles biocompatibility and cellular uptake in a 3D human lung model. Nanomedicine (Lond.), 2020, 15(3), 259-271.
[http://dx.doi.org/10.2217/nnm-2019-0256] [PMID: 31789097]
[119]
Varshosaz, J.; Ghaffari, S.; Mirshojaei, S.F.; Jafarian, A.; Atyabi, F.; Kobarfard, F.; Azarmi, S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed Res. Int., 2013, 2013, 1-8.
[http://dx.doi.org/10.1155/2013/136859] [PMID: 23984315]
[120]
Kesharwani, R.; Sachan, A.; Singh, S.; Patel, D. Formulation and evaluation of Solid Lipid Nanoparticle (SLN) based topical gel of etoricoxib. J. Appl. Pharm. Sci., 2016, 6, 124-131.
[http://dx.doi.org/10.7324/JAPS.2016.601017]
[121]
Beniwal, A.; Choudhary, H. Rosuvastatin calcium-loaded Solid Lipid Nanoparticles (SLN) using design of experiment approach for oral delivery. International Journal of Chemical and Life Sciences, 2017, 6(5), 2029.
[http://dx.doi.org/10.21746/ijcls.2017.5.1]
[122]
Saari, M.; Vidgren, M.T.; Koskinen, M.O.; Turjanmaa, V.M.H.; Nieminen, M.M. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int. J. Pharm., 1999, 181(1), 1-9.
[http://dx.doi.org/10.1016/S0378-5173(98)00398-6] [PMID: 10370197]
[123]
Lin, C.; Wong, B.C.K.; Chen, H.; Bian, Z.; Zhang, G.; Zhang, X.; Kashif Riaz, M.; Tyagi, D.; Lin, G.; Zhang, Y.; Wang, J.; Lu, A.; Yang, Z. Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci. Rep., 2017, 7(1), 1097.
[http://dx.doi.org/10.1038/s41598-017-00957-4] [PMID: 28428618]
[124]
Muppidi, K.; Wang, J.; Betageri, G.; Pumerantz, A.S. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob. Agents Chemother., 2011, 55(10), 4537-4542.
[http://dx.doi.org/10.1128/AAC.00713-11] [PMID: 21788465]
[125]
Willis, L.; Hayes, D., Jr; Mansour, H.M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung, 2012, 190(3), 251-262.
[http://dx.doi.org/10.1007/s00408-011-9360-x] [PMID: 22274758]
[126]
Bassetti, M.; Vena, A.; Russo, A.; Peghin, M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs, 2020, 80(13), 1309-1318.
[http://dx.doi.org/10.1007/s40265-020-01359-z] [PMID: 32691293]
[127]
Lim, Y.H.; Tiemann, K.M.; Hunstad, D.A.; Elsabahy, M.; Wooley, K.L. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2016, 8(6), 842-871.
[http://dx.doi.org/10.1002/wnan.1401] [PMID: 27016134]
[128]
Park, C.W.; Li, X.; Vogt, F.G.; Hayes, D., Jr; Zwischenberger, J.B.; Park, E.S.; Mansour, H.M. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int. J. Pharm., 2013, 455(1-2), 374-392.
[http://dx.doi.org/10.1016/j.ijpharm.2013.06.047] [PMID: 23820131]
[129]
Dawson, M.; Wirtz, D.; Hanes, J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J. Biol. Chem., 2003, 278(50), 50393-50401.
[http://dx.doi.org/10.1074/jbc.M309026200] [PMID: 13679362]
[130]
Forier, K.; Messiaen, A.S.; Raemdonck, K.; Deschout, H.; Rejman, J.; De Baets, F.; Nelis, H.; De Smedt, S.C.; Demeester, J.; Coenye, T.; Braeckmans, K. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine (Lond.), 2013, 8(6), 935-949.
[http://dx.doi.org/10.2217/nnm.12.129] [PMID: 23035662]
[131]
Chen, E.Y.T.; Wang, Y.C.; Chen, C.S.; Chin, W.C. Functionalized positive nanoparticles reduce mucin swelling and dispersion. PLoS One, 2010, 5(11), e15434.
[http://dx.doi.org/10.1371/journal.pone.0015434] [PMID: 21085670]
[132]
Jokerst, J.V.; Lobovkina, T.; Zare, R.N.; Gambhir, S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.), 2011, 6(4), 715-728.
[http://dx.doi.org/10.2217/nnm.11.19] [PMID: 21718180]
[133]
Paul, P.; Sengupta, S.; Mukherjee, B.; Shaw, T.K.; Gaonkar, R.H.; Debnath, M.C. Chitosan-coated nanoparticles enhanced lung pharmacokinetic profile of voriconazole upon pulmonary delivery in mice. Nanomedicine (Lond.), 2018, 13(5), 501-520.
[http://dx.doi.org/10.2217/nnm-2017-0291] [PMID: 29383985]
[134]
Ungaro, F.; d’Angelo, I.; Coletta, C.; d’Emmanuele di Villa Bianca, R.; Sorrentino, R.; Perfetto, B.; Tufano, M.A.; Miro, A.; La Rotonda, M.I.; Quaglia, F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release, 2012, 157(1), 149-159.
[http://dx.doi.org/10.1016/j.jconrel.2011.08.010] [PMID: 21864595]
[135]
Ohashi, K.; Kabasawa, T.; Ozeki, T.; Okada, H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release, 2009, 135(1), 19-24.
[http://dx.doi.org/10.1016/j.jconrel.2008.11.027] [PMID: 19121349]
[136]
Chauhan, N.; Jaggi, M.; Chauhan, S.C.; Yallapu, M.M. COVID-19: Fighting the invisible enemy with microRNA. Expert Rev. Anti Infect. Ther., 2021, 19(2), 137-145.
[137]
Mohamed, A.; Kunda, N.K.; Ross, K.; Hutcheon, G.A.; Saleem, I.Y. Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD). Eur. J. Pharm. Biopharm., 2019, 136, 1-8.
[http://dx.doi.org/10.1016/j.ejpb.2019.01.002] [PMID: 30615927]
[138]
Sanders, N.; Rudolph, C.; Braeckmans, K.; De Smedt, S.C.; Demeester, J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev., 2009, 61(2), 115-127.
[http://dx.doi.org/10.1016/j.addr.2008.09.011] [PMID: 19146894]
[139]
Suk, J.S.; Lai, S.K.; Boylan, N.J.; Dawson, M.R.; Boyle, M.P.; Hanes, J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N -acetyl cysteine. Nanomedicine (Lond.), 2011, 6(2), 365-375.
[http://dx.doi.org/10.2217/nnm.10.123] [PMID: 21385138]
[140]
Hadinoto, K.; Sundaresan, A.; Cheow, W.S. Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. Eur. J. Pharm. Biopharm., 2013, 85(3)(3 Pt A), 427-443.
[http://dx.doi.org/10.1016/j.ejpb.2013.07.002] [PMID: 23872180]
[141]
Cheow, W.S.; Chang, M.W.; Hadinoto, K. The roles of lipid in anti-biofilm efficacy of lipid–polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf. A Physicochem. Eng. Asp., 2011, 389(1-3), 158-165.
[http://dx.doi.org/10.1016/j.colsurfa.2011.08.035]
[142]
Abbasi, E.; Aval, S.F.; Akbarzadeh, A.; Milani, M.; Nasrabadi, H.T.; Joo, S.W.; Hanifehpour, Y.; Nejati-Koshki, K.; Pashaei-Asl, R. Dendrimers: Synthesis, applications, and properties. Nanoscale Res. Lett., 2014, 9(1), 247.
[http://dx.doi.org/10.1186/1556-276X-9-247] [PMID: 24994950]
[143]
Kesharwani, P.; Jain, K.; Jain, N.K. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci., 2014, 39(2), 268-307.
[http://dx.doi.org/10.1016/j.progpolymsci.2013.07.005]
[144]
Ryan, G.M.; Kaminskas, L.M.; Kelly, B.D.; Owen, D.J.; McIntosh, M.P.; Porter, C.J.H. Pulmonary administration of PEGylated polylysine dendrimers: Absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm., 2013, 10(8), 2986-2995.
[http://dx.doi.org/10.1021/mp400091n] [PMID: 23750747]
[145]
Rinto, R.; Lestari, S.D.; Baehaki, A.; Sari, Y. The effect of degradation time in the simulated gastric fluid for bioactive compounds from bekasam. IOP Conf. Ser. Earth Environ. Sci., 2020, 404(1), 012018.
[http://dx.doi.org/10.1088/1755-1315/404/1/012018]
[146]
Astrup, T.; Crookston, J.; Macintyre, A. Proteolytic enzymes in blood. Acta Physiol. Scand., 1950, 21(2-3), 238-249.
[http://dx.doi.org/10.1111/j.1748-1716.1950.tb00732.x] [PMID: 14856775]
[147]
ClinicalTrials.gov. Monovalent recombinant COVID19 vaccine; , 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04453852
[148]
Guerrini, G.; Magrì, D.; Gioria, S.; Medaglini, D.; Calzolai, L. Characterization of nanoparticles-based vaccines for COVID-19. Nat. Nanotechnol., 2022, 17(6), 570-576.
[http://dx.doi.org/10.1038/s41565-022-01129-w] [PMID: 35710950]
[149]
Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C.; Bailey, R.; Swanson, K.A.; Roychoudhury, S.; Koury, K.; Li, P.; Kalina, W.V.; Cooper, D.; Frenck, R.W.; Hammitt, L.L.; Türeci, Ö.; Nell, H.; Schaefer, A.; Ünal, S.; Tresnan, D.B.; Mather, S.; Dormitzer, P.R.; Şahin, U.; Jansen, K.U.; Gruber, W.C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. Engl. N. J. Med., 2020, 383(27), 2603-2615.
[http://dx.doi.org/10.1056/NEJMoa2034577]
[150]
Schoenmaker, L.; Witzigmann, D.; Kulkarni, J.A.; Verbeke, R.; Kersten, G.; Jiskoot, W.; Crommelin, D.J.A. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int. J. Pharm., 2021, 601, 120586.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120586] [PMID: 33839230]
[151]
Heath, P.T.; Galiza, E.P.; Baxter, D.N.; Boffito, M.; Browne, D.; Burns, F.; Chadwick, D.R.; Clark, R.; Cosgrove, C.; Galloway, J.; Goodman, A.L.; Heer, A.; Higham, A.; Iyengar, S.; Jamal, A.; Jeanes, C.; Kalra, P.A.; Kyriakidou, C.; McAuley, D.F.; Meyrick, A.; Minassian, A.M.; Minton, J.; Moore, P.; Munsoor, I.; Nicholls, H.; Osanlou, O.; Packham, J.; Pretswell, C.H.; Alberto, S.F.R.; Saralaya, D.; Sheridan, R.P.; Smith, R.; Soiza, R.L.; Swift, P.A.; Thomson, E.C.; Turner, J.; Viljoen, M.E.; Albert, G.; Cho, I.; Dubovsky, F.; Glenn, G.; Rivers, J.; Robertson, A.; Smith, K. Toback, Seth Safety and efficacy of NVX-CoV2373 covid-19 vaccine. N. Engl. J. Med., 2021, 385(13), 1172-1183.
[http://dx.doi.org/10.1056/NEJMoa2107659]
[152]
Magnusson, S.E.; Altenburg, A.F.; Bengtsson, K.L.; Bosman, F.; de Vries, R.D.; Rimmelzwaan, G.F.; Stertman, L. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol. Res., 2018, 66(2), 224-233.
[http://dx.doi.org/10.1007/s12026-018-8991-x] [PMID: 29594879]
[153]
Dhawan, A.; Sharma, V. Toxicity assessment of nanomaterials: Methods and challenges. Anal. Bioanal. Chem., 2010, 398(2), 589-605.
[http://dx.doi.org/10.1007/s00216-010-3996-x] [PMID: 20652549]
[154]
Landen, C.N., Jr; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-Berestein, G.; Sood, A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res., 2005, 65(15), 6910-6918.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-0530] [PMID: 16061675]
[155]
Höbel, S.; Aigner, A. Nonviral delivery platform for therapeutic RNAi: Pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. Future Oncol., 2009, 5(1), 13-17.
[http://dx.doi.org/10.2217/14796694.5.1.13] [PMID: 19243292]
[156]
Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release, 2006, 114(1), 100-109.
[http://dx.doi.org/10.1016/j.jconrel.2006.04.014] [PMID: 16831482]
[157]
Barreto, J.A.; O’Malley, W.; Kubeil, M.; Graham, B.; Stephan, H.; Spiccia, L. Nanomaterials: Applications in cancer imaging and therapy. Adv. Mater., 2011, 23(12), H18-H40.
[http://dx.doi.org/10.1002/adma.201100140] [PMID: 21433100]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy